Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Gilead Drug Approval Fuels Interest In CAR-T Space: 3 Stocks To Consider

By Zacks Investment ResearchStock MarketsOct 22, 2017 09:23PM ET
www.investing.com/analysis/gilead-drug-approval-fuels-interest-in-cart-space-3-stocks-to-consider-200220365
Gilead Drug Approval Fuels Interest In CAR-T Space: 3 Stocks To Consider
By Zacks Investment Research   |  Oct 22, 2017 09:23PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

Interest in the CAR-T (chimeric antigen receptor T cells) space continues to build up with the FDA giving its nod to the second CAR-T therapy last week. Gilead Sciences’s (NASDAQ:GILD) Yescarta, a cell-based gene therapy, gained approval for the treatment of adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment. This makes Yescarta the second gene therapy to gain FDA approval, the first being Novartis AG’s (NYSE:NVS) Kymriah. Kymriah was approved in late August 2017 for certain pediatric and young adult patients with a form of acute lymphoblastic leukemia (“ALL”).

How Does CAR-T Cell Therapy Work?

CAR-T falls under the ambit of cellular immunotherapy which involves using a patient’s own immune cells to attack and get rid of harmful disease cells in the body.

The CAR-T approach involves the collection of a patient’s T cells, their genetic modification outside the body, the incorporation of specific receptors which target cancer cells and finally, the re-infusion of the modified T cells back into the patient.

There is a lot of enthusiasm for CAR-T as studies have shown that it can help achieve durable complete responses in some leukemias and lymphomas, including in patients who have suffered multiple relapses. However, CAR-T comes with its own set of challenges including a high level of R&D investment as well as safety issues like serious immune toxicity (“CRS”) or neurotoxicity. In fact, both Kymriah and Yescarta have boxed warnings in their labels for CRS and neurologic toxicities. These treatments will also not come cheap. While Novartis has set a price of $475,000 for Kymriah, the list price for Gilead’s Yescarta is $373,000.

The FDA’s Stance

With the FDA granting back-to-back approvals to two CAR-T treatments, it looks like the regulatory environment might well be encouraging for gene cell therapy candidates.

In fact, FDA Commissioner Scott Gottlieb said that the approval of Yescarta shows the continued momentum in this promising new area of medicine. The agency intends to release a comprehensive policy on how it plans to support the development of cell-based regenerative medicine.

CAR-T Stocks in Focus

Given the increased focus on this corner of the immuno-oncology market and the huge commercial potential for approved treatments in this market, here is a look at 3 companies that are working on CAR-T cell treatments.

Juno Therapeutics, Inc. (NASDAQ:JUNO) : Biopharmaceutical company, Juno, is focused on the development of innovative cellular immunotherapies for the treatment of cancer. Juno’s cell-based cancer immunotherapies are based on chimeric antigen receptor and high-affinity T cell receptor technologies. The company has several cell-based candidates in its pipeline targeting a variety of B-cell malignancies as well as multiple solid tumors and multiple myeloma.

Although the company suffered a major setback with the development of its erstwhile lead pipeline candidate due to safety issues (including patient deaths), Juno is now focusing on JCAR017, a next-generation CAR-T cell product that targets CD19. JCAR017 is currently in a registrational study for non-Hodgkin’s lymphoma ("NHL"). The company also has a strong partner in Celgene Corporation (NASDAQ:CELG) .

Juno stock has gained 131.9% year to date, substantially outperforming the 10.2% rally of the industry it belongs to.

bluebird bio, Inc. (NASDAQ:BLUE) : bluebird is another clinical-stage company working on developing gene therapies for serious genetic diseases and T cell-based immunotherapies for cancer. The company’s anti-BCMA CAR T therapy, bb21217, is being evaluated for relapsed/refractory multiple myeloma. bb21217 as well as bb2121 are being developed in collaboration with Celgene.

bluebird stock has gained 131% year to date, substantially outperforming the 10.2% rally of the industry it belongs to.

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) : Biotech company ZIOPHARM uses innovative gene expression, control and cell technologies to provide safe, effective and scalable cell- and viral-based therapies for cancer and graft-versus-host-disease. ZIOPHARM’s immune-oncology platform includes CAR-T as well as other adoptive cell-based approaches.

While announcing second quarter results, the company had said that within its CAR+ T programs, it is continuing with a phase I second generation study of CD19 specific CAR+ T for lymphoid malignancies and expects to move third generation CD19 with mbIL15 towards an early-stage study evaluating point-of-care. Plans are also on to commence a phase I study with CD33-specific CAR+ T for relapsed/refractory acute myeloid leukemia (AML) this year. ZIOPHARM’s shares are up 0.9% so far in 2017.

Juno, bluebird and ZIOPHARM are all Zacks Rank #3 (Hold) stocks - you can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

In addition to the above three, companies like Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) and Cellectis also have a presence in this area. However, Cellectis, a French biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), has run into a roadblock with the FDA placing a clinical hold on a couple of early-stage studies being conducted on UCART123. The hold came into place after the company reported a death in one of the studies.

Going forward, we expect investor focus to remain in this corner of the immuno-oncology market. In addition to tracking the performance of Kymriah and Yescarta, we believe more deals will be announced in the cell therapy space.

Will You Make a Fortune on the Shift to Electric Cars?

Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.

With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.

It's not the one you think.

See This Ticker Free >>



Novartis AG (NVS): Free Stock Analysis Report

Gilead Sciences, Inc. (GILD): Free Stock Analysis Report

Celgene Corporation (CELG): Free Stock Analysis Report

ZIOPHARM Oncology Inc (ZIOP): Free Stock Analysis Report

bluebird bio, Inc. (BLUE): Free Stock Analysis Report

Juno Therapeutics, Inc. (JUNO): Free Stock Analysis Report

Bellicum Pharmaceuticals, Inc. (BLCM): Free Stock Analysis Report

Original post
Gilead Drug Approval Fuels Interest In CAR-T Space: 3 Stocks To Consider
 

Related Articles

Thomas Hughes
Beware The Rebound In Retail Stocks By Thomas Hughes - May 27, 2022

The S&P Retail ETF (NYSE:XRT) is rebounding, but we don’t think investors should cheer too loudly. The move is driven by the combination of oversold markets and mixed...

Jea Yu
Affirm Stock Has Affirmed A Bottom By Jea Yu  - May 27, 2022 1

Buy now and pay later purchase financing provider Affirm Holdings (NASDAQ:AFRM) stock is rebounding after bottoming out at $13.64. The buy-now-pay-later (BNPL) platform had a very...

Gilead Drug Approval Fuels Interest In CAR-T Space: 3 Stocks To Consider

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email